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Invasive Candidiasis:
Epidemiology and Risk Factors
Jorge Alberto Cortés and Ivohne Fernanda Corrales
Abstract
Invasive candidiasis is a severe infection caused by the yeast of the genus
Candida. This highly lethal infection can affect any organs, but it is usually identi-
fied by the growth of the yeast in bloodstream samples. Although C. albicans was
the most frequently found species, there has been a global trend to the non-albicans
isolates. The appearance of C. auris, a newly identified species around the world, is
a cause of concern because of resistance to antifungals. In this chapter, the
epidemiology and risk factors for the acquisition of candidemia and other forms of
invasive candidiasis are reviewed, while showing the current knowledge of
worldwide epidemiology.
Keywords: Candida, Candida albicans, invasive, candidiasis, fungemia,
candidemia, intensive care units, surgery, immunosuppression, microbiota
1. Introduction
Candidiasis is the common name for diseases produced by the yeast of the genus
Candida. This is the most frequently found yeast in human microbiome and is
capable of causing disease at different sites of the human anatomy and with diverse
severity [1]. Invasive candidiasis refers to severe fungal infections in which the
yeast might be found in deep organs or blood [2]. Due to the difficulty of identify-
ing Candida yeasts in tissues, since it requires a biopsy of the tissue compromised,
invasive candidiasis in the literature has been primarily found as bloodstream
infections, alone or with accompanying tissue compromise.
2. Microbiology and environment
Candida species are yeasts (i.e., they mainly have a unicellular form). They are
small, with a size of 4–6 μm, with a thin wall and an ovoid aspect, named blasto-
spores [3]. They reproduce by budding. Using the microscope, these yeasts can be
seen in the form of pseudohyphae, budding cells that do not separate, or truly
hyphae (multicellular organisms). Candida organisms belong to the class Ascomy-
cetes, order Saccharomycetales, and family Saccharomycetes [4]. There are around
200 species of Candida; however, a limited number has a pathogenic effect on
humans [4]. Table 1 shows the most frequently found species. Due to their previous
prevalence and pathogenic significance, they were usually classified as albicans
1
versus non-albicans Candida species. However, due to changes in epidemiology, this
overall classification might not be useful any more.
They grow in agar as colonies with a smooth, creamy, white appearance. The
formal identification can be made by use of biochemical physiological reactions,
which can differentiate an important number of isolates. The metabolic reactions
include carbohydrate fermentation, nitrate use, and urease production.
Candida yeasts might be seen with direct stains like KOH with 10–20% concen-
trations, but also with others like Gram, Giemsa, Wright para amino-salicylic (PAS)
acid, and Papanicolaou. In direct stains, Candida might be seen as big aggregates of
blastoconidiae, with short and large pseudohyphae. Usual growth media include
Sabouraud agar, brain infusion, heart, and yeast extract. While C. albicans and C.
dubliniensis grow in usual Sabouraud agar with antibiotics, some species might be
inhibited by cycloheximide [4]. Usual growth time is 2–3 days at 28–37°C. Chro-
mogenic agars were developed more than 20 years ago and are capable of identify-
ing the most commonly found species, and speciation is desirable due to pathogenic
and susceptibility differences among them. There are several commercial methods
using chromogenic agars. The sensitivity for detection of Candida yeast is over 95%,
usually with a low number or no false positive results [5]. The finding of a positive
culture does not imply an invasive infection, and a special consideration has to be
made for isolates from sterile sites.
Candida species differ in their susceptibility to different antifungals available in
different countries. Most frequently found isolates of C. albicans and C. parapsilosis
are susceptible to all antifungals available. C. tropicalis might have some resistance
to fluconazole, while maintaining susceptibility to equinocandins and amphotericin
B. C. glabrata tends to have higher minimal inhibitory concentrations (MICs) to
azoles, while remaining susceptible to equinocandins and amphotericin B. C.
lusitaniae isolates can be found to be resistant to amphotericin B. The recently found
that C. auris is frequently found multidrug resistant.
Susceptibility testing can be performed by different methods, including broth
microdilution (recommended in the USA and Europe), but there are other different
commercial methods available in hospitals. Two slightly different standards for
susceptibility testing are currently available. One is suggested by the Clinical Labo-
ratory Standards Institute (CLSI, in USA), while the other is proposed by the
European Committee on Antimicrobial Susceptibility Testing (EUCAST), spon-
sored by the European Society of Clinical Microbiology and Infectious Diseases
Species Characteristic
C. albicans Usually the most frequently found
C. parapsilosis
complex
C. parapsilosis, C. orthopsilosis, C. metapsilosis
C. tropicalis Related to cancer
C. glabrata Usually resistant to azoles, seen more frequently in developed scenarios and
older patients
C. guilliermondii Less pathogenicity
C. lusitaniae Potentially resistant to amphotericin
C. krusei Intrinsically resistant to azoles
C. dubliniensis Difficult to differentiate from C. albicans
C. auris Responsible for a global outbreak
Table 1.
Most frequently found Candida species in human disease.
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(ESCMID). Basic differences between both methodologies include time and instru-
ment to read the results. Different clinical breakpoints have been established for the
most commonly found species, with the intention of differentiating the risk of
clinical failure after treatment. The experience with fluconazole has allowed to
develop better prediction models, in comparison with newer antifungals [6]. In
summary, an isolate of Candida is exposed to different concentrations of the anti-
fungal and the in vitro growth is observed. If there is no important growth, deter-
mined optically or by a spectrophotometer, a minimal inhibitory concentration
(MIC) is established. As mentioned, data from clinical trials and observation
cohorts with common species such as C. albicans and C. glabrata have allowed to
identify clinically relevant breakpoints to differentiate isolates with low MICs (sus-
ceptible); intermediate MICs (also called susceptible dose dependent—SDD), in
which an increase in the administered antifungal can control the infection; and high
MICs, (resistant), for which a lower probability of success is expected. For some
other uncommon species, only epidemiological breakpoints are available. These
breakpoints are also MICs, but there is no clinical evidence of correlation with the
clinical outcome after treatment. However, since MICs are higher than those in
usual isolates, a worse outcome might be expected. These breakpoints are expected
to identify isolates with natural or acquired mechanisms of antifungal resistance.
The epidemiological breakpoints are based on the statistical distribution of MICs of
the wild-type isolates (i.e., isolates without any previous resistant pressure). Com-
mercial methods are modifications of the standard methods that use dyes to identify
the growth (e.g., Alamar Blue) of the microorganisms. Examples include
Sensititre™ and YeastOne™. Other methods are based on agar, in which a gradient
of the antifungal is diffused in the solid growth media, which allows to directly read
the MIC (e.g., Etest™) [7].
Candida species are part of the human microbiota and they live in human
mucosae and skin. Candida species can be found in the ground, animals, fruits and
vegetables, and in the hospital environment. It is not considered a laboratory con-
taminant. It is considered an endogenous pathogen since around 60–75% of the
people might have it in the mucosal epithelium, especially in the gastrointestinal
and genital tracts [8]. In the hospital area, they have been found over inanimate
surfaces, including percutaneous catheters and tubes. They might even be found in
the hands of healthcare workers. Among patients in healthcare centers, the coloni-
zation of the mucosae has been related to antibiotic use and hospitalization time [9].
In patients in the intensive care unit (ICU), colonization might be found in different
anatomical sites with ample variations [10, 11]. Pharyngeal colonization rate has
been found to be between 34 and 65%, gastric colonization between 42 and 67%,
rectal colonization between 21 and 40%, and colonization in other sites between 11
and 40% [10, 11]. These data show the possibility of colonization that has this
microorganism in patients under stress conditions (in this case, severe disease). In
the normal host, the colonization rate might reach over 50% in the mouth, 40% in
the vaginal tissue in women, and 73% in any mucosa of the gastrointestinal or
genital tracts [8].
3. Pathogenesis
Candida species have some characteristics that permit them to adapt to different
environments and act as an opportunistic pathogen. These factors include adapta-
tion to pH changes, permitting to survive in blood or some alkaline environments,
as well as in the acidic environment of the vaginal tissue; these species have
adhesins, mannoproteins with capacity to adhere to different cells and cell products.
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These adherence proteins allow the isolates to survive in tissues, but also over
inanimate surfaces that have been exposed to plasma or inflammatory host proteins
like urinary or endotracheal catheters. Candida species have also important
enzymes as virulence factors, since some of them have keratinolytic, peptidase,
hemolysin, and other effects. One of the most frequently mentioned virulence
factors include the possibility of a morphologic transition, which has been exten-
sively studied. It refers to the possibility of morphologic changes of blastoconidia to
pseudohyphae to real hyphae. These changes are stimulated by environmental
conditions. The filamentous forms are related to active infection in the host, except
for C. glabrata. Other factors related to pathogenicity or virulence also include a
phenotyping change, the possibility of adopting different phenotypes in the cul-
tures (color or aspect of the colonies), and biofilm formation. A biofilm is a large
community of symbiotic microorganisms adhered to a surface. This conformation
allows the microorganisms to have a highly defensive capacity, persistence, and a
highly antimicrobial resistance.
As mentioned before, Candidamight be part of the human flora. The majority of
infections are due to the interplay between the risk factors, that pose a risk to the
individual, the interaction with other microorganisms present in the skin or mucosa
and the total quantity of microorganisms present. This was demonstrated some
years ago in an experiment [12]. An individual ingested directly from a C. albicans
culture. After some hours, this immunocompetent individual began to have fever.
After 12 hours, Candida isolates were found in the bloodstream and, after 16 hours,
they were found in the urine. After 24 hours, Candida isolates were cleared from
the body and the individual returned to the normal state. This experiment proved
the importance of colonization. With posterior evidence, it has been demonstrated
that the first step to have an infection is colonization by Candida especially in the
gastrointestinal tract, but otherwise in contact with indwelling catheters, the skin,
or wounds that may permit the entry of the yeast into the bloodstream. In another
critical observation, patients in the ICU were followed with cultures. The coloniza-
tion index (it is the proportion of positive cultures for the same Candida species
taken from different anatomical places) increased over time and was correlated to
the probability of developing an invasive candidiasis [9]. These studies suggest that
in individuals with Candida colonization, those factors that promote the grow of the
yeast, by eliminating the bacteria that can compete for the environment, that alter
or facilitate the penetration of the yeast to the bloodstream (lesions in the gastroin-
testinal mucosa, indwelling catheters) will promote the entry of Candida yeast to
the blood, while the net state of compromise of the immune system will affect the
probability of fungal clearance and the possibility of seeding on specific organs.
4. Epidemiology
4.1 Risk factors
4.1.1 Candida infection in the intensive care unit
Patients in the ICU have the highest rate of Candida infections in the hospital. In
comparison with patients in other wards, patients in the ICU have more frequent
abdominal surgery, stay longer in the hospital, and are more severely ill [13]. They
also have a worse prognosis in the long term, with increased mortality after one year
of the event.
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4.1.1.1 Vascular devices
Patients in the ICU have higher rates of Candida infection in comparison with
patients in other wards. Critically ill patients often require multiple vascular and
other indwelling devices for their management and candidemia has been related to
catheter colonization in 20–80% of the cases [14, 15]. One study in Japan identified
the presence of a solid tumor, the use of total parenteral nutrition, and the admin-
istration of anti-anaerobic agents as the main risk factors for the development of
Candida infections [16]. As mentioned, Candida colonization of the catheter might
provide a route for entering into the bloodstream without a heavy gastrointestinal
colonization. Studies have shown that Candida catheter-related bloodstream infec-
tions have a shorter time to grow in comparison with those from other sources [14].
With a breakpoint of 30 hours, the time to grow in patients with Candida blood-
stream infection might identify 100% of those catheter-related infection. Probably,
patients with catheter-related infection have a higher inoculum, which would
explain the faster time to grow and the fact that observational studies have shown a
lower mortality when catheter is removed [17, 18]. On the other hand, patients with
non-catheter-related candidemia were more seriously ill, had a higher mortality,
and the removal of the catheter did not affect the outcome [17].
4.1.1.2 Parenteral nutrition
Another commonly identified risk factor is the use of parenteral nutrition or the
length of its use [15, 19]. This group of patients shares several risk factors, but
parenteral nutrition has been identified in multivariate analysis [20]. Usually, they
have an abdominal procedure (see below) and they require parenteral nutrition for
several days. Lack of appropriate measures to handle the nutrition, colonization
of the catheter or the ports used to infuse it, and probably the availability of
optimal growing conditions are conditions related to its use. But clearly, the use of
parenteral nutrition leads to the development of mucosal atrophy and a loss of
mucosal epithelial barrier function [21], which might affect the relationship
between microorganisms in the gut and the possibility of gaining access to blood
vessels. Total parenteral nutrition has also a profound effect in the gastrointestinal
microbiome [22].
4.1.1.3 Surgical procedures
Several studies have shown the relationship between candidemia and a previous
surgical procedure [19, 23], specially an abdominal surgery. There are several
explanations to this observation, but gut manipulation, and the effect of resected
sections over the gut microbiology, microbiota abundance, and epithelial function
might contribute to the possibility of candidemia. Studies have shown that patients
with high anastomotic leak, as well as those with recurrent gastrointestinal perfo-
ration, or acute necrotizing pancreatitis, have a higher risk of candidemia [15].
4.1.1.4 Antibiotic use
Almost all studies of candidemia have shown an extremely high use of antibi-
otics previous to the identification of bloodstream or tissue infection. The propor-
tion of patients with antibiotic use is over 80% [24]. The number and spectrum of
the antibiotics used might affect the risk of candidemia. Antimicrobials also have an
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effect over gut microbiota, and some studies have shown some impact from antibi-
otics with anti-anaerobic effect, and those with higher gastrointestinal concentra-
tion [25]. They contribute to the observed increased colonization over time
observed in patients in the ICU. With more antibiotic effect, there is a net decrease
in the number of species in the gastrointestinal tract, an increase in the number of
patients colonized, and the proportion of them being heavily colonized [26].
4.1.1.5 Other risk factors
Studies have identified several risk factors that alone, or in combination, might
increase the probability of having candidemia. The presence of renal failure, the use
of antihistaminic blockers, the severity of illness, and the length of stay in the ICU
contribute to colonization and development of candidemia [24, 27]. All these factors
contribute to the acquisition of Candida, its colonization, or failure in the gastroin-
testinal epithelial function, favoring the entry of the yeast to the bloodstream.
4.1.1.6 Scores based on risk factors
The identification of risk factors lead to the use of some scores based in the
presence of such factors to identify patients with higher risk of Candida infection.
The first and most simple of those scores was introduced in mid-1990s. Pittet et al.
in a surgical ICU followed prospectively patients admitted in the ward with cultures
of several anatomical sites [9]. They defined the colonization index as previously
stated, establishing that with an index of 0.5 or more (50% of the sites with the
same species), there was an increase in the risk of candidemia. With a lower
colonization index, the risk in the original study was 0%. They defined a second
index based on the density of colonization, in which patients overpassing some
thresholds in the number of colonies isolated per site, being able to improve the
identification of the patients at risk.
A second score to identify risk factors in patients was developed in Spain by
León and his collaborators [20]. They identified colonization (with a different
definition from that used by Pittet et al.), surgery at ICU admission, and use of total
parenteral nutrition as risk factors independently associated with candidemia. They
also identified sepsis as independently related, but this is clearly more a clinical
syndrome than a risk factor. A third score was developed by a multicenter collabo-
ration group, in which they again identified the same risk factors [28]: antibiotic
use, having an intravascular catheter, in conjunction with at least two additional
risk factors such as any surgery, immunosuppressive use, pancreatitis, total paren-
teral nutrition, dialysis, or steroid use.
Common to these scores has been the presence of the aforementioned risk
factors. The problem, however, is that such scores identify a huge number of
patients at risk with a final intermediate risk of developing candidemia, in a range
from 7 to 30% [29, 30]. The great advantage of the diagnostic scores relies in their
high negative predictive value. Patients with a negative score have a low probability
of candidemia, below a 1% probability.
4.1.2 Hematological malignancy, solid organ transplantation, and other
immunosuppressive states
These disorders share a common factor: immunosuppression. However, differ-
ent types of immunocompromise entail different risks for the patients. The inci-
dence of candidemia among patients with cancer is higher in comparison with other
patients in the hospital. In a multicenter study in Greece, patients with
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hematological disease had an incidence of candidemia of 1.4 cases per 1000 admis-
sions, while other patients hospitalized had an incidence of 0.83 cases per 1000
admissions [31]. A multicenter European study found an incidence of 1.2% cases of
candidemia among patients with bone marrow transplantation (BMT) and leuke-
mia [32]. An Italian multicenter study from a surveillance network showed a
diminishing trend for candidemia among patients with cancer, especially among
those with acute myeloid leukemia [33]. Whether this trend can be inferred to other
European countries or not is not known, and the most likely explanation for this
decrease in the number of cases could be related to the use of prophylaxis among
those patients with acute leukemia with posaconazole. In general, non-albicans
Candida species are more frequently found among these groups of patients [31].
4.1.2.1 Neutropenia
Neutropenia, a count of leukocytes in peripheral blood below 500 cells per μl, is
the common risk factor among patients with hematological disorders (i.e., leuke-
mia, lymphoma, multiple myeloma among others) as well as those with bone
marrow transplantation (BMT). Neutropenia might be a consequence of the activity
of the hematological disease, an effect of chemotherapeutic strategies or side effect
of multiple medications including antimicrobials. It also is a marker of the intensity
of chemotherapy. Patients with chemotherapy-induced neutropenia accumulate
various risk factors: they usually receive wide spectrum antibiotics for several days,
they have serious gastrointestinal epithelial tissue dysfunction, usually with diar-
rhea and signs of mucosal damage, and the use of vascular catheters for the infusion
of chemotherapeutic drugs and antibiotics [34]. Several studies have shown that
isolates of C. tropicalis are more frequently found among patients with cancer [35].
A study that looked for risk factors identified underlying leukemia as one of the
major risk factors, together with chronic lung disease [36].
In patients with prolonged neutropenia, a condition called hepatosplenic candi-
diasis might be seen. In it, seeding of yeasts occurs during the neutropenic phase
which might be not clinically evident until neutropenia recovery. In these patients,
fever persists and lesions can be seen in the liver, usually known as bull-eye lesions
[37] (Figure 1).
Figure 1.
Tomographic image of liver and spleen showing abscesses (bull’s eye, arrows) and hypodense lesions in a patient
with chronic disseminated candidiasis. Reproduced with permission from Cortés et al. [37].
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4.1.2.2 Concurrent conditions in patients with cancer
In patients with cancer and candidemia, several factors were identified in com-
parison with those with cancer and bacterial infections [38]. Total parenteral nutri-
tion over 5 days, urinary catheter for more than 2 days, distant metastasis of cancer,
and gastrointestinal cancer were independent risk factors. Patients with solid
tumors might accumulate factors as patients in critical care, since they have
abdominal surgery (gastrointestinal neoplasm), require vascular catheters for
extended periods of time (for chemotherapy or antibiotics), total parenteral nutri-
tion and received antibiotics frequently [39]. A study to identify factors predicting
catheter-related infections with Candida identified solid tumors and the use of anti-
anaerobic antibiotics as risk factors [16].
Among patients with leukemia and BMT, the risk factors for occurrence of
candidemia included bone marrow or cord blood stem cell source, T-cell depletion,
use of total body irradiation, and acute graft versus host disease [32]. These data
were derived from a huge multicenter registry of patients with cancer and trans-
plantation, which allowed to identify more precisely the risk factors.
4.1.3 Neonates
Newborns have no gastrointestinal flora at birth and have to be colonized by
enterobacteria and other microorganisms, which is made via maternal breast feed-
ing. Any alteration in the normal process can lead to colonization by pathogenic
microorganisms, including yeasts [40]. Neonates in the intensive care unit usually
have limited breastfeeding, indwelling vascular catheters, total parenteral nutrition,
and antibiotics [41]. Such combination of risk factors put. this group of patients at a
higer risk of infection, reaching over 10% of patients in units with extreme pre-
matures and low weight at birth (the group that requires more invasive interven-
tions) [42]. Some studies have illustrated this relationship with proportion of
candidemia between 3 and 10% among those with a weight of less than 1000 g
while showing an incidence of less than 1% for those weighting over 2500 g [43]. In
this scenario, disseminated candidemia can be found and near 10% of those with
invasive disease can compromise the central nervous system. Another important
risk factor includes the time that the patient has been in the unit [44]; clearly,
patients with low weight, lower gestational age, and more comorbidity tend to
spend more time in the neonatal ICU and to accumulate other risk factors (surgery,
indwelling catheter, antibiotics, etc.) [45]. There are some high-risk units, in which
the incidence of candidemia traditionally has been high, usually over 10% of the
admitted cases. In this scenario, prophylaxis has been suggested for the prevention
of infection [46].
4.1.4 Outbreaks
Candida yeast can survive in inanimate surfaces and in the hands of healthcare
personnel, which confers the risk of outbreak and cross dissemination among high-
risk units such as neonatal, intensive care, and surgical intensive care units [44, 47].
An interesting study in Iceland over a long period of time allowed to confirm the
presence of clonal isolates of different Candida species among patients in the ICU
and other wards [48]. The proportion of patients involved at one time with an
outbreak of all patients with Candida isolates might be as high as 38%. Other study
in Spain showed that clusters (of patients with candidemia) were possible with C.
albicans and C. parapsilosis, and reached in a period as high as 40% of the isolates
[49]. Besides, the use of chlorhexidine has been shown to diminish the number of
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candidemia events in patients in the ICU, showing the importance of colonization
and cross infection among high-risk patients and establishing this recommendation
in the guidelines for the prevention of candidemia [50].
As shown, colonization is the preliminary step to infection. Besides, a number of
interventions are common to immunosuppressed and critically ill patients including
indwelling catheters (urinary and vascular), severity of illness, total parenteral
nutrition, etc. These conditions predispose the patients to cross contamination. An
outbreak among newborns was demonstrated to be due to poor practices of catheter
ports disinfection [51].
A study in China in a cancer institute showed that 21 out of 36 episodes of
candidemia were caused by two endemic genotypes [52]. In this study, gastrointes-
tinal cancer and insertion of a nasogastric tube were related to infection. As men-
tioned before, cancer patients with solid and hematological tumors share several of
the risk factors of colonization and infection.
4.2 Global epidemiology
Since 2013, the Leading International Fungal Education (LIFE) portal has facil-
itated an important effort to know the epidemiology and burden of fungal infec-
tions around the world and allowed a better understanding of their epidemiology in
different countries [53]. The real incidence of candidemia is difficult to calculate
due to differences in the approach. While studies based on hospitals might
overestimate the importance of some groups of high-risk patients, they are difficult
to compare. Data from population studies might reflect better the real situation, but
this kind of information is scarce. Studies have shown ample differences in the
incidence in some regions and at specific times [54].
4.2.1 Changing trend for non-albicans Candida
Traditionally, C. albicans had been the most frequently isolated species. How-
ever, a trend toward non-albicans species has been observed around the world in
the last 15 years. In United States, C. glabrata has been identified as second in
frequency, while C. parapsilosis or C. tropicalis dispute this place in other regions.
Table 2 shows the proportion of isolates in some studies around the world in the last
10 years [55–59].
Two studies deserve a detailed description. The first one is a multicenter study
from the Southeast Asia region, including 25 hospitals from 6 countries: China,
Hong Kong, India, Singapore, Taiwan, and Thailand [60]. They found differences
between the countries that include the frequency of C. tropicalis isolation, being
Area and
publication year
C. albicans (%) C. glabrata (%) C. tropicalis C. parapsilosis References
USA 2012 38 29 17 10 [49]
Latin America 2013 37.6 6.3 17.6 26.5 [48]
Spain 2014 45.4 13.4 7.7 24.9 [50]
Asia-Pacific region
2016
20–55 5–22 2–20 8–27 [51]
France 2014 56 18.6 9.3 11.5 [52]
Table 2.
Proportion of Candida species in selected studies of candidemia around the world.
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more commonly found in hematology-oncology wards and in tropical areas. This
study confirmed the observed trend for a lower frequency of C. albicans isolates.
The other study is the Latin-American surveillance study [55]. It involved patients
from 20 centers in 7 seven countries: Argentina, Brazil, Colombia, Chile, Honduras,
Mexico, and Venezuela. Important differences were seen among institutions,
reflecting difference in healthcare systems, access, population types, and risk fac-
tors. However, in these two studies, the incidence of candidemia is higher than in
developed countries in Europe and North America. In Latin America, C. parapsilosis
frequency is over 30% of the isolates while this place is occupied by C. tropicalis in
the Asian countries.
4.2.2 Epidemiology in Europe and North America
There are data from some population surveillance surveys in Europe and United
States. In general, the incidence might be lower than in some other areas of the
world. Table 3 shows the incidence from data from North America and European
countries [61–77]. In Europe, the highest incidence has been observed in Hungary,
while in North America the highest incidence has been seen in some cities in United
States.
4.2.3 Epidemiology in Central and South America and the Caribbean
This region has profound differences in healthcare systems, access to care, and
medical technology development. With a transition toward a higher income, a
growing number of institutions with capacity to attend cancer patients, and more
Country/region Publication Year Incidence (per 100.000 inhabitants) References
Belgium 2015 5 [54]
Denmark 2008 10.4 [55]
Finland 2010 2.8 [56]
Germany 2015 4.6 [57]
Hungary 2015 11 [58]
Ireland 2015 7.3 [59]
Norway 2018 3.8 [60]
Portugal 2017 2.57 [61]
Romania 2018 6.8 [62]
Russia 2015 8.29 [63]
Serbia 2018 10 [64]
Spain 2015 8.1 [65]
Sweden 2013 4.2 [66]
Ukraine 2015 5.8 [67]
Canada 2017 2.91 [68]
México 2015 8.6 [69]
USA 2015 9.5–14.4 [70]
Table 3.
Estimated incidence of invasive candidiasis or candidemia in countries of the European or North American
regions.
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complex medical needs, the number of candidemia cases seems to be higher than in
developed countries.
Ample information exists about the problem in Brazil, where a number of
studies have been carried out in high-complexity hospitals in the main cities of the
country [78, 79]. These studies show a higher frequency of invasive candidiasis in
comparison with developed countries, an increased isolation of C. glabrata for the
last period and an important exposition to fluconazole (which might have increased
the selection for non-albicans species) [79]. Country-wise estimates for incidence
are shown in Table 4 [80–89].
4.2.4 Epidemiology in Africa and Asia
A multicenter in Asia gathered information from various countries, including
nine hospitals from China [60]. The incidence rate among patients hospitalized was
0.38 per 1000 admissions, which is lower than that observed in the Latin-American
region with 1.08 cases per 1000 admissions [55]. The estimated incidence of
candidemia in countries in Asia is shown in Table 5 [90–100]. In Asia, the highest
incidence has been observed in Pakistan, followed by Qatar and Israel. In China,
geographic variations in the causative species and susceptibilities were noted, with
increasing isolates resistant to fluconazole [101]. The numbers for the African
countries are lacking and for some countries like Algeria, Burkina Faso, Cameroon,
Egypt, Malawi, Mozambique, and Tanzania, the estimated incidence is 5.8 cases per
100,000 inhabitants, a standard calculation based on previously reported incidence
in other countries [102–108].
4.2.5 Azole resistance epidemiology
Azole-resistant Candida isolates have had an increased frequency over the years.
Susceptibility changes with the species, and fluconazole use has been related to an
increase in the frequency of C. glabrata and C. krusei, and a low increase in the
number of resistant C. albicans or C. tropicalis. A large multicenter study in French
ICUs identified the age and the exposure to antifungals as independent risk factors
for resistance [109]. Patients with isolates resistant to fluconazole tended to be older
than 15 years and to have been exposed to this drug, while those with
Country/region Publication year Incidence (per 100,000 inhabitants) References
Argentina 2018 6.25 [71]
Brazil 2016 14.9 [72]
Chile 2017 5.8 [73]
Colombia 2018 14.7 [74]
Ecuador 2017 7.2 [75]
Guatemala 2017 6.4 [76]
Jamaica 2015 5.8 [77]
Perú 2017 5.8 [78]
Trinidad and Tobago 2015 5.8 [79]
Uruguay 2018 36.5 [80]
Table 4.
Estimated incidence of invasive candidiasis or candidemia in countries of Central and South America and the
Caribbean.
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equinocandin-resistant isolates were younger and found to have been exposed to
equinocandin. In general, risk factors for resistance remain the same as in resistant
bacteria: immunosuppression, previous use of antifungals [110, 111]. Other
identified risk factors include chronic renal failure and anti-tuberculous treatment.
This last one might be due to a medication interaction.
Among patients with cancer, not only are non-albicans Candida species more
frequently found, but also resistance to azoles has increased. In a study in Greece,
resistance to fluconazole among patients with cancer reached 27% [31]. Since azoles
have been widely used in the prophylaxis against fungal infections among cancer
patients [112, 113], this seems to be a natural consequence of their use. Among
patients with cancer, isolates of C. tropicalis, C. glabrata, and C. krusei have
increased resistant proportions [35].
4.2.6 Candida auris global outbreak
Up to 2009, there was no report on C. auris. In that year, a clinical case from
Japan was published, and 2 years later three cases of candidemia were identified
[114, 115]. During the following years, isolates of C. auris were responsible of out-
breaks around the world, affecting hospitals in India, Pakistan, South Africa,
England, and Venezuela [116–119]. It was detected in the USA in 2013 with
growing frequency [120]. A worldwide alarm was raised in 2016 because of two
problems related to this species. The first one was the difficulty in proper identifi-
cation [121]. C. auris is most commonly identified as C. haemulonii and
Rhodotorula glutinis by the commercial systems and sometimes as C. famata, C.
guilliermondii, and C. parapsilosis [121]. The other problem is the higher frequency
of resistance to multiple antifungals, including azoles and amphotericin [122]. Cur-
rently, C. auris has been isolated in several areas in the USA, continental Europe,
and the Caribbean coast of South America, including the islands [123–125], and
continue to extend to other areas, where reports are being published. A search for
virulence factors in the isolates of C. auris has shown some different properties,
specially the capacity for biofilm formation [126]. Molecular observations have
diverse geographic dissemination caused by unique clades in each geographic
region [127].
Country/region Publication year Incidence (per 100,000 inhabitants) References
Bangladesh 2017 5 [83]
Israel 2015 11 [84]
Jordan 2018 5.75 [85]
Kazakhstan 2018 4.3 [86]
Korea 2017 4.57 [87]
Malaysia 2018 5.8 [88]
Pakistan 2017 21 [89]
Philippines 2017 2.25 [90]
Qatar 2015 15.4 [91]
Thailand 2015 13.3 [92]
Uzbekistan 2017 5.93 [93]
Table 5.
Estimated incidence of invasive candidiasis or candidemia in countries of Africa and Asia.
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5. Outcomes
Patients with candidemia and cancer are considered to have higher mortality,
but this issue has not been clearly assessed. Older studies showed an attributable
mortality around 40%. Although mortality among patients with candidemia or
invasive candidiasis is reported usually around 40–50%, they occur in patients with
important comorbidity. A recent multicenter analysis showed a crude mortality for
patients with candidemia of 53%, while those without candidemia had a mortality
of 26% [128]. After adjusting in a propensity score analysis, the crude mortality was
51% for the candidemic patients and 37% for the others and the difference was not
statistically significant. The study shows that an increase in mortality might exist
for those patients with candidemia, but it is clear that patients with candidemia also
have severe comorbidity and some of them can die with candidemia instead of
because of it.
Risk factors for mortality among patients with candidemia include ascites, pres-
ence of septic shock, ICU admission, concomitant bacterial infection and catheter-
related infections [129]. Studies with diverse population have shown that elderly
patients have higher mortality [130]. In these patients, a combination of comorbid-
ity, poor clinical situation, and more pathogenic species might contribute to their
mortality [131]. A pooled analysis from patients included in randomized clinical
trials comparing micafungin and amphotericin B showed differences among geo-
graphic regions, severity of disease (measured with Apache score for patients crit-
ically ill), and catheter removal [132]. In those with abdominal candidiasis, the lack
of control of the source of infection has been related to increased risk of death [133].
Among patients with cancer, risk factor for mortality includes infection by a C.
tropicalis isolate, a high Charlson index score, neutropenia, and septic shock
[35, 134]. One multicenter study identified tachypnea as a risk factor for mortality
[135], while others identified respiratory failure and use of non-antifungal medica-
tions [39]. Besides, antifungal prophylaxis and remission of the underlying cancer
had a protective effect over mortality [135].
The impact of the antifungal treatment in the mortality of patients with
candidemia is not entirely clear. There are several constrains to identify the benefits
of the antifungal treatment: An important proportion of patients did not receive
antifungal treatment despite the identification of a bloodstream infection; of those
that receive the treatment, some of them can receive it as empirical treatment,
based on the risk factors, clinical condition, while others have an antifungal started
upon detection of candidemia. Besides, some of them are infected with a resistant
isolate and some do poorly, and an additional antifungal must be started. Although
meta-analysis with patient-level data has showed the benefit of equinocandin use
(in contrast to azole treatment) [136], neither the cohort data [137], nor the ran-
domized trials have confirmed this finding [138]. There is an additional complica-
tion in understanding this relationship; the laboratory breakpoints for identification
of susceptible versus resistant isolates have changed over the time, especially for
azoles [130]. Among those patients with septic shock, the delay in the administra-
tion of the antifungal treatment has been associated with increased mortality.
6. Conclusion
Candidemia is the most frequently found form of invasive candidiasis. The
Candida species might be found as part of the flora and patients with previous
colonization are at risk of developing an infection. They share some common factors
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like antibiotic exposure, use of indwelling catheters, parenteral nutrition, and sur-
gery. These factors affect the normal physiology of the gastrointestinal tract or
provide access to the bloodstream to yeast in patients with some comorbidities, in
critical care or with immunosuppressive states.
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